Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.27B P/E - EPS this Y 7.20% Ern Qtrly Grth -
Income -238.72M Forward P/E -6.28 EPS next Y -31.60% 50D Avg Chg -26.00%
Sales 38.39M PEG -8.26 EPS past 5Y - 200D Avg Chg -36.00%
Dividend N/A Price/Book 2.21 EPS next 5Y 1.00% 52W High Chg -59.00%
Recommedations 1.80 Quick Ratio 12.87 Shares Outstanding 142.18M 52W Low Chg 24.00%
Insider Own 34.72% ROA -12.66% Shares Float 74.64M Beta 1.00
Inst Own 61.60% ROE -21.83% Shares Shorted/Prior 4.73M/7.85M Price 15.94
Gross Margin -131.98% Profit Margin - Avg. Volume 1,675,812 Target Price 37.19
Oper. Margin -629.44% Earnings Date Nov 2 Volume 916,603 Change -0.50%
Allogene Therapeutics, Inc. News
10/15/21 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
10/15/21 Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
10/14/21 Cathie Wood’s Ark Funds Built Up Big Stakes in Crispr Stock. The Stock Tumbled.
10/13/21 Why Crispr's Gene-Editing Dive Helped Reinvigorate Its Chief Rival, Allogene
10/12/21 Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Intrinsic Value Is Potentially 96% Above Its Share Price
10/11/21 Allogene Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
10/11/21 Company News for Oct 11, 2021
10/11/21 Are Options Traders Betting on a Big Move in Allogene (ALLO) Stock?
10/08/21 ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
10/08/21 Why Allogene Therapeutics Stock Is Getting Hammered Today
10/08/21 Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge
10/08/21 Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
10/08/21 Allogene Tanks as FDA Stops All Trials After Safety Scare
10/08/21 FDA Holds Allogene’s AlloCAR T Clinical Trials; Shares Crash 33%
10/08/21 5 Stocks To Watch For October 8, 2021
10/08/21 Tesla, Quidel, Chubb Rise Premarket; Allogene Tumbles
10/07/21 Peninsula cell therapy company's stock falls sharply as FDA halts clinical trial
10/07/21 Allogene Therapeutics stock drops as much as 40% as FDA puts hold on cancer drug study
10/07/21 Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.

ALLO Chatroom

User Image wompwomp13 Posted - 2 hours ago

$ALLO Hey everyone, could I ask why this stock went down so much lately? Did a clinical trial go bad? Not trolling either, legit question. Thanks in advance.

User Image Shrkdkthsjfk Posted - 4 hours ago

$ALLO FDA decision week? 🤔

User Image Carl_saunders Posted - 8 hours ago

$ALLO I love ALLO! Made tons with it! Another to check out is KPTI. $5 stock with JP Morgan PT of $27. 80% institutional ownership and shorted HUGE! Major catalyst coming

User Image Hajimee Posted - 9 hours ago

$CRTX same like $ALLO next day +40%

User Image efgeneric Posted - 12 hours ago

$ALLO At this point, ALLO looks more or less stable which was a first objective. Longs should reasonably assume that sellers interest is diminishing. One level of interest could be EMA 20 on daily (17.95 at the moment). I am slowly accumulating. Risk of farther negative news still exists, so, as always, management of position is in order. OT: for those who in $PYPL - I hope you are experienced and disciplined trader/investor. You will get hurt if you are not. TA imply a chance of short squeeze within next 5 trading days. Do your own DD! Once again, this is a high risk/high reward trade.

User Image Makisksvavbss Posted - 13 hours ago

$ALLO not much movement any expectation of when we see the hold fr FDA changing to go ahead ? That will definitely spike the price

User Image FuzzyMuffin Posted - 14 hours ago

$ALLO this will settle around $18 pre news from FDA.

User Image JoeStocks99 Posted - 15 hours ago

$ALLO 20 and 25 dollar calls. Ez money.

User Image Maxx101 Posted - 16 hours ago

$ALLO let’s moon

User Image NickyProfits Posted - 1 day ago

$ALLO closing over $16 is all I needed. Push for $20 begins this week folks.

User Image Maxx101 Posted - 1 day ago

$ALLO steady is the key

User Image debbiekatz Posted - 1 day ago

$allo at 16.27 has been very slow but keep swinging. posted previously at 13.87

User Image MaK613 Posted - 1 day ago

Back in April Dr. Jantz (the CSO/Co-Founder) of Precision Bio $DTIL was asked about the potential for #GeneEditing to cause "catastrophic (chromosomal) rearrangements" such a #Chromothripsis I think it's even more relevant now in light of $ALLO 501a CAR-T hold (and the rest of their pipeline) Asked and answered in 60 seconds https://player.vimeo.com/video/633292420?h=f76cd1279e

User Image Stockbeep_Scanner Posted - 1 day ago

Breaking out in the morning $NVDA $UPS $CRWD $SOL $ALLO +5 more results stockbeep.com/bo-oct26a

User Image Doorkey Posted - 1 day ago

$ALLO $$$$$$ Shaved AEHR OCGN loading here!

User Image Mick3y Posted - 1 day ago

$ALLO let's go! 🔥🔥🔥🔥 Can we get a pump here!

User Image ballyhooo Posted - 1 day ago

$ALLO good news is coming just a matter of time!

User Image ballyhooo Posted - 1 day ago

$ALLO good news is coming

User Image Maxx101 Posted - 1 day ago

$ALLO up and up

User Image universityoftokyo Posted - 1 day ago

$ALLO I would honestly prefer that this stays lower. These fat 3.5% rips are only bring average costs up, and increasing the pain if there is eventually bad news. Keep this low.

User Image mboss91 Posted - 1 day ago

$ALLO bought in last week, looking for a reversal soon!

User Image NickyProfits Posted - 1 day ago

$ALLO let’s go!!!

User Image NickyProfits Posted - 1 day ago

$ALLO reverse coming soon amigos! Stay tuned for $17

User Image intartag Posted - 2 days ago

$ALLO i like what I am seeing … very interesting video from a doctor about allo vs crisper https://youtu.be/cVELISVWoQI

User Image Kingjake26 Posted - 2 days ago

$ALLO please go to $24 dollars.

User Image Market_TREX Posted - 2 days ago

$ALLO anyone gambling on Nov calls on this one?

User Image NickyProfits Posted - 2 days ago

$ALLO $14.99 buy orders are set, but I highly doubt we will touch those levels this week. This stock should be sitting around $16.90-.95 Let’s go!!! Everyone will shocked when they wake up & see this thing up 130 percent

User Image ccledez Posted - 2 days ago

$ALLO how long does FDA take to remove clinical hold, on average? Anyone know?

User Image MoneyMakingMacBlast Posted - 2 days ago

$ALLO this does the same thing every day!!!!!

User Image Maxx101 Posted - 2 days ago

$ALLO hmmm…I guess we still have time

Analyst Ratings
JMP Securities Market Outperform Oct 12, 21
Stifel Hold Oct 8, 21
RBC Capital Outperform Oct 8, 21
Goldman Sachs Neutral Oct 8, 21
Raymond James Outperform Sep 24, 21
Raymond James Outperform Sep 23, 21
Truist Securities Buy May 20, 21
B. Riley Securities Buy May 14, 21
HC Wainwright & Co. Buy Mar 1, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Jan 19 Sell 31.82 30,000 954,600 1,152,595 01/19/21
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Nov 18 Sell 32.8 15,000 492,000 1,182,595 11/18/20
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Oct 16 Sell 41.24 15,000 618,600 1,197,595 10/16/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 09 Option 2.27 35,264 80,049 147,879 10/09/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 09 Sell 41 44,574 1,827,534 108,370 10/09/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 08 Option 2.27 35,264 80,049 161,536 10/08/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 08 Sell 40 44,574 1,782,960 117,680 10/08/20
Bhavnagri Veer General Counsel General Counsel Oct 08 Option 2.27 10,000 22,700 363,902 10/08/20
Bhavnagri Veer General Counsel General Counsel Oct 08 Sell 40 10,000 400,000 353,902 10/08/20
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Sep 22 Sell 35.92 15,000 538,800 1,212,595 09/22/20